Glucophage

Selected form

Metformin Hydrochloride

Method of action: Drugs Used In Diabets, Hypoglycemic

Treatment option: Change Of Life, Obesity, Diabetes Mellitus, Type 2 Diabetes

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glucophage

What is Glucophage?

Glucophage is an oral medication primarily used to help manage blood sugar levels in individuals with type 2 diabetes. The active ingredient in Glucophage is metformin, which belongs to a class of medications known as biguanides. Unlike some other diabetes medications, it does not increase the production of insulin; instead, it focuses on improving how the body handles the insulin it already produces.

How It Works

Glucophage helps control blood sugar through three primary mechanisms:

Reducing Hepatic Glucose Production: It limits the amount of sugar that the liver releases into the bloodstream.
Improving Insulin Sensitivity: It enhances the ability of muscle and fat tissues to take up and use existing insulin more effectively.
Slowing Intestinal Absorption: It decreases the rate at which sugar is absorbed from the digestive tract after eating.

Clinical Role

In the management of type 2 diabetes, Glucophage is often utilized as a foundational therapy alongside lifestyle modifications, such as dietary changes and regular physical activity. Because it addresses the body's resistance to insulin, it is a common choice for long-term glycemic control. It can be used alone or in combination with other glucose-lowering agents when a single medication is not sufficient to maintain target blood sugar levels.

Regulatory References

What side effects are possible with Glucophage?

Possible Side Effects and Safety Information

The safety profile of Glucophage (Metformin Hydrochloride) is defined by a spectrum of adverse reactions documented by regulatory authorities, ranging from common, typically transient effects to rare, serious metabolic risks.

Documented Adverse Reactions

The most frequently reported adverse reactions are classified as Very Common (affecting more than 1 in 10 patients) and are primarily concentrated in the Gastrointestinal system. These effects, which include diarrhea, nausea, vomiting, abdominal pain, and loss of appetite, are characteristically observed at the beginning of treatment and generally resolve spontaneously. A Common side effect (affecting up to 1 in 10 patients) is taste disturbance, often described as a metallic taste. Adverse reactions classified as Very Rare (affecting up to 1 in 10,000 patients) include liver function test abnormalities and hepatitis; these conditions typically reverse upon discontinuation of the medicine.

Serious Adverse Reactions and Key Constraints

Metformin is associated with the rare but serious metabolic complication of Lactic Acidosis, which is primarily linked to the accumulation of the medicine in the body. This condition is a central concern that dictates specific safety constraints in official regulatory documents. Another risk associated with long-term use is the decrease in serum Vitamin B12 levels, which can, in rare instances, lead to clinically significant deficiency, such as megaloblastic anemia.

Population-Specific Safety Notes

The medicine is contraindicated in severe renal impairment (eGFR below 30 mL/minute/1.73 m^2) due to the elevated risk of Lactic Acidosis. This risk necessitates that older adults receive more frequent renal function assessment, as their reduced renal capacity increases susceptibility. Furthermore, Glucophage is generally avoided in individuals with hepatic disease. Specific procedures, such as those involving intravascular iodinated contrast media, require temporary discontinuation of the medicine due to the acute risk posed to renal function.

Overdose and Emergency Response

The most serious and life-threatening outcome associated with Glucophage (Metformin Hydrochloride) overdose is Lactic Acidosis, a severe metabolic complication confirmed by regulatory authorities. This condition is categorized as a medical emergency and necessitates immediate regulatory action. All patients, or those supervising their care, must understand that the drug should be immediately discontinued upon any suspicion of overdose or metabolic distress. Prompt hospitalization is required to institute general supportive measures.

Overdose is often insidious, presenting with nonspecific, officially documented clinical manifestations. These signs include malaise, myalgias (muscle pain), respiratory distress, increasing somnolence, and hypotension. The official diagnosis relies on physiological findings such as significantly elevated blood lactate concentrations (generally exceeding 5 mmol/L) and decreased blood pH. Any of these symptoms require that urgent medical help be sought.

Management of this severe outcome requires specific regulatory procedures. Prompt hemodialysis is recommended to clear the accumulated metformin from the circulation and correct the underlying acidosis, as no specific antidote is documented. Risk factors that increase the likelihood of metformin accumulation and Lactic Acidosis—including renal impairment, hepatic insufficiency, advanced age, and excessive alcohol intake—are highlighted in the regulatory labeling.

Therapeutic Uses of Glucophage

What Glucophage treats: main uses and benefits

Glucophage (metformin) is commonly used as a foundational therapy for conditions characterized by periods of heightened symptoms related to systemic glucose imbalance. This medication is considered relevant for easing the overall burden of symptoms in patients with Type 2 Diabetes Mellitus. It helps control high blood sugar levels that can lead to long-term health complications. The main therapeutic areas include addressing high blood sugar levels (hyperglycemia) and supporting the metabolic management of Polycystic Ovary Syndrome (PCOS).

Easing Symptom Clusters and Supporting Stability

Glucophage plays a role in managing symptoms that create noticeable physiological strain, such as excessive thirst, constant fatigue, and frequent urination. It may assist with maintaining a sense of stability when symptoms are more noticeable, particularly in clinical settings where supportive symptom management is appropriate. It helps to manage the underlying metabolic issues that cause day-to-day discomfort. This supportive relief contributes to improved comfort during symptomatic periods.

Quick Fact: Relief for Systemic Imbalance This medication supports the body during phases of temporary physiological imbalance associated with glucose regulation.

Regulatory References

NIH MedlinePlus overview on Metformin

Eligibility and Restrictions for Use

Official Eligibility and Restrictions

Glucophage (Metformin Hydrochloride) is officially indicated for use in adults and pediatric patients 10 years of age and older (immediate-release formulation only) with Type 2 Diabetes Mellitus. Eligibility is strictly defined by regulatory documentation, focusing on contraindications and patient status.

Absolute Contraindications

Use is contraindicated in patients with severe renal impairment (estimated Glomerular Filtration Rate, eGFR, below 30 mL/min/1.73 m^2), acute or chronic metabolic acidosis (including diabetic ketoacidosis), and known hypersensitivity to Metformin. The medication must also be temporarily discontinued before or during iodinated contrast imaging procedures in certain at-risk patients.

Populations Requiring Restriction

Therapy initiation is not recommended for patients with an eGFR between 30 and 45 mL/min/1.73 m^2. Furthermore, official labeling advises avoiding use in patients with clinical evidence of hepatic impairment (liver disease) or excessive alcohol intake. Glucophage is not generally recommended for routine management during pregnancy or lactation. Geriatric patients require more frequent assessment of renal function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents categorize interactions with Glucophage (metformin) based on their potential for altering drug concentrations or increasing specific risks, such as lactic acidosis or hypoglycemia.

Pharmacokinetic and Clearance Interactions

Certain medicinal products can reduce the renal clearance of metformin, leading to increased levels of Glucophage in the body. Drugs that are eliminated by renal tubular secretion (cationic drugs) may fall into this category. Specific medicines mentioned in official labeling include cimetidine, ranolazine, vandetanib, and dolutegravir.

Pharmacodynamic and Risk Interactions

Hypoglycemia Risk: Concomitant use with insulin or insulin secretagogues is associated with an increased risk of low blood sugar due to additive effects.
Hyperglycemic Agents: Medicines that tend to produce hyperglycemia, such as corticosteroids, diuretics, phenothiazines, and thyroid products, may counteract the glucose-lowering effects of Glucophage.
Lactic Acidosis Risk: Co-administration with Carbonic Anhydrase Inhibitors may increase the risk of lactic acidosis; monitoring may be recommended.

Procedural and Substance Constraints

Iodinated Contrast Materials: Glucophage must be temporarily discontinued at the time of, or prior to, an iodinated contrast imaging procedure and withheld for 48 hours afterward. Reinitiation is permitted only after renal function is re-evaluated and confirmed as normal.
Alcohol: Patients are cautioned against excessive acute or chronic alcohol intake due to the potential to potentiate the effect of metformin on lactate metabolism.

Mechanism of Action

Glucophage (metformin) modulates glucose homeostasis through multiple non-pancreatic mechanisms. Its chief action is the reduction of hepatic glucose production. This effect is mediated by the inhibition of the mitochondrial respiratory chain complex I within hepatocytes, which decreases the production of ATP. The resultant lower ATP:AMP ratio leads to the activation of AMP-activated protein kinase (AMPK).

AMPK activation is the central mechanistic cascade. Activated AMPK phosphorylates and inhibits various enzymes crucial for gluconeogenesis, such as fructose-1,6-bisphosphatase and glucose-6-phosphatase. This activity directly reduces the rate of endogenous glucose synthesis and release from the liver.

At the systemic level, Glucophage also influences peripheral tissue function. It increases the sensitivity of target tissues (like muscle and adipose cells) to circulating insulin. This action improves the efficiency of insulin signaling, thereby facilitating greater glucose uptake and utilization by these peripheral cells.

Dosage and Administration Information

How to Use Glucophage — Official Administration Guidelines

Glucophage (metformin hydrochloride) is administered orally and must be taken with meals to improve tolerability.

Dosing and Timing

The recommended starting dose for adults is typically 500 mg twice a day or 850 mg once a day. The dose is then gradually increased (titrated) in increments, often 500 mg weekly or 850 mg every two weeks, based on patient needs and tolerability, up to a maximum dose of 2000–2550 mg daily, depending on the specific formulation.

For pediatric patients (ages 10 and older), the usual starting dose is 500 mg twice daily, taken with meals, with a maximum daily dose of 2000 mg in divided doses.

Administration Detail	Immediate-Release (Glucophage)	Extended-Release (Glucophage XR)
Route & Timing	Oral, with meals (2–3 times daily)	Oral, once daily with the evening meal
Preparation	Swallow tablet whole.	Swallow tablet whole; do not crush, cut, or chew.
Missed Dose	Skip the missed dose and take the next dose at the regularly scheduled time. Do not take two doses at once.

Special Procedural Conditions

Glucophage must be temporarily discontinued at the time of, or prior to, any iodinated contrast imaging procedure. The medication should not be restarted until at least 48 hours after the procedure, and only if renal function has been re-evaluated and found to be stable or within acceptable limits. Discontinuation is also required before and after major surgical procedures involving general, spinal, or peridural anesthesia.

Recent Clinical Evidence

Research evidence / Overview of studies for Glucophage

Evidence for Use in Type 2 Diabetes Mellitus

The foundational research for Glucophage (metformin) consists primarily of large-scale Randomized Controlled Trials (RCTs). These studies were used in research exploring how blood sugar levels changed in observed patient populations. Researchers monitored key biomarkers, such as Glycated Hemoglobin ( HbA1 c) and Fasting Plasma Glucose (FPG), which are used to measure the body’s glucose control over time. Studies were applied in research contexts involving both newly diagnosed adults and those whose condition was no longer adequately managed by diet and exercise alone.

Research has explored Glucophage for prevention. Large prevention trials examined whether taking the medication would delay or reduce the rate at which high-risk individuals—those with prediabetes or Impaired Glucose Tolerance—developed full Type 2 Diabetes. Findings in these large studies indicated patterns where the rate of progression to a diagnosis of T2DM differed in the observed populations receiving Glucophage compared to those receiving placebo.

Long-Term Studies and Follow-up for Diabetes

Research has monitored the long-term impact of Glucophage beyond initial blood sugar control, with some follow-up studies extending for ten years or more. These extended studies focused on long-term clinical endpoints such as all-cause mortality and the incidence of serious cardiovascular events like heart attack and stroke. This research describes patterns related to how the medicine was associated with major complication rates in specific groups of patients, particularly those who were overweight or obese when they started treatment.

While some landmark long-term trials described patterns of changes in outcomes related to cardiovascular events and mortality in certain studied subgroups, findings across all subsequent Systematic Reviews and Meta-analyses have been mixed or inconsistent. The degree of certainty remains low regarding consistent findings across all studies concerning long-term cardiovascular outcomes for all studied patient groups.

Research on Related Metabolic Conditions (PCOS)

Research examined Glucophage in the context of Polycystic Ovary Syndrome (PCOS), a condition involving periods of heightened symptoms related to hormonal and systemic imbalance. The trials monitored outcomes related to female reproductive health, including ovulation rate, clinical pregnancy rate, and the risk of Ovarian Hyperstimulation Syndrome (OHSS) in women undergoing fertility treatments. Findings indicated a pattern where some trials reported measurements of ovulation rate and clinical pregnancy rate.

However, research suggests that the evidence quality varies across studies. The primary limitation is the limited number of RCTs that specifically focused on and were large enough to provide sufficient findings on the key long-term endpoint of live birth rate. Furthermore, limited information is available regarding the medication's effect on general cardiovascular or cancer risk in women with PCOS.

Key Studies & References The Diabetes Prevention Program (DPP): A Randomized, Controlled Trial of Lifestyle Intervention or Metformin

Frequently Asked Questions (FAQ)

Common questions about Glucophage (FAQ)

Q: Is Glucophage the same thing as metformin?

Glucophage is one of the brand names for the generic drug substance metformin hydrochloride. According to official product descriptions, both names refer to the same medicine, which is used to manage blood glucose levels in people with type 2 diabetes.

Q: What is Glucophage used for besides diabetes?

Glucophage is officially indicated only for the treatment of type 2 diabetes mellitus. Its use for any other condition is considered outside of the official indication as listed on regulatory labels.

Q: Does Glucophage help with weight loss?

The medicine is not officially indicated or approved for weight loss. Its primary goal is to help control blood glucose in people with type 2 diabetes. While clinical studies may describe changes in body weight, its use is strictly for blood sugar management.

Q: How quickly does Glucophage start working after I take it?

According to the official product information, the concentration of the medicine in the blood typically reaches its maximum level for immediate-release tablets within a few hours. When taken regularly, steady-state concentrations (consistent levels in the body) are usually achieved within one to two days.

Q: If I stop taking Glucophage, what happens?

Regulatory documents require the temporary discontinuation of Glucophage only for specific medical procedures, such as surgery or certain imaging tests. Discussing any changes to treatment with a healthcare provider is generally recommended to manage blood sugar control.

Q: Can Glucophage interact with pain relievers like ibuprofen?

Certain pain relievers known as Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which include ibuprofen, may potentially increase the risk of a serious metabolic complication called lactic acidosis. This potential increase in risk is potentially associated with a decline in kidney function, which is critical for clearing Glucophage from the body.

Q: Are there certain supplements or vitamins that should be avoided while taking Glucophage?

Official information cautions that Glucophage use, particularly long-term, is associated with a decrease in blood serum Vitamin B12 levels. Patients may be monitored for this. No other common vitamins or supplements are typically listed as strict contraindications in the official drug label.

Q: Is Glucophage safe to use during pregnancy?

Available data regarding the medicine’s use during pregnancy are insufficient to determine the potential risk of birth defects or miscarriage. Official information notes that poorly controlled diabetes itself poses risks to both the mother and the fetus.

Q: Can Glucophage be used while breastfeeding?

Studies indicate that Glucophage passes into breast milk in low amounts, and no adverse effects have been reported in breastfed infants based on limited available data. However, official labeling may advise caution, especially when nursing a newborn or premature baby.

Q: Can people who don't have diabetes take Glucophage?

Glucophage is formally indicated by regulatory bodies only for people with type 2 diabetes mellitus. Its use by individuals who do not meet the criteria for this condition is not covered by the official indications.

Q: Is Glucophage a controlled substance?

Glucophage (metformin) is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or other major regulatory bodies.

Q: Why is Glucophage often the first medicine prescribed for diabetes?

Studies referenced in regulatory documents, such as the UKPDS trial, examined patterns where the medicine was associated with reduced diabetes-related complications and mortality in specific patient groups. These findings have influenced medical guidelines to support its use as an initial therapy.

Q: Are there any foods I should avoid completely when taking Glucophage?

Official information advises patients to avoid excessive acute or chronic alcohol intake. This is because alcohol may increase the potential for the serious metabolic complication known as lactic acidosis. No specific food types other than alcohol are generally listed as contraindications.

Q: Is it possible to take Glucophage and still control my diabetes with diet and exercise alone?

Glucophage is officially indicated to be used as an adjunct to diet and exercise to improve blood sugar control. The medicine is intended to complement, not replace, positive lifestyle measures.

Q: What makes Glucophage different from sulfonylureas?

Glucophage belongs to a class of medicines called biguanides. Its primary mechanisms of action—which include reducing glucose production in the liver—are distinctly different from the actions of sulfonylureas, which work by stimulating the pancreas to release more insulin.

Q: What does 'contraindication' mean in relation to Glucophage?

A contraindication is a specific factor or condition that regulatory documents state makes the use of a medicine improper or inadvisable. For Glucophage, major contraindications include having severely reduced kidney function or certain acute conditions that increase the risk of lactic acidosis.

Q: Can I take Glucophage if I have heart failure?

Regulatory warnings mention that several serious cases of lactic acidosis have occurred in the setting of acute congestive heart failure, particularly when accompanied by poor blood flow and low oxygen levels. The medicine is generally recommended to be discontinued by a healthcare provider if such an acute event occurs.

Q: Is Glucophage linked to issues with thyroid function?

Official drug interaction warnings note that medicines used to treat thyroid dysfunction (thyroid products) may sometimes counteract the glucose-lowering effects of Glucophage. Regulatory information does not state that Glucophage directly causes primary dysfunction of the thyroid gland or hormone levels.

Q: What are the signs of a severe allergic reaction to Glucophage?

While rare, severe metabolic complications like lactic acidosis may present with nonspecific signs such as generalized discomfort (malaise), muscle pain (myalgias), breathing difficulties, and abdominal pain. Regulatory postmarketing reports for similar medicines have also included severe skin reactions like anaphylaxis (a serious, rapid-onset allergic reaction).

Q: Is it necessary to check blood sugar levels while taking Glucophage?

Regulatory documents and guidelines recommend that key indicators of blood sugar control, such as Glycated Hemoglobin (HbA1c) levels, be monitored periodically. These monitoring results are typically used to assess the medicine’s effectiveness.

Q: What types of allergic reactions are listed in official documents for Glucophage?

Official documents cite post-marketing experience with specific hypersensitivity reactions, which are allergic responses. These have included reports of anaphylaxis (a serious, rapid-onset allergic reaction), angioedema (swelling beneath the skin), and rare, severe skin conditions like bullous pemphigoid.

Q: Are there research findings about Glucophage and cancer prevention?

Long-term studies have examined patient outcomes beyond blood sugar control, including the potential association between Glucophage use and various clinical events. While some research has explored the medicine’s effect on cancer risk, the degree of certainty remains low, and official documents note limited findings on this topic across all studied patient groups.

Q: How long does the body take to clear Glucophage?

Regulatory pharmacokinetic information states that following oral administration, the plasma elimination half-life—the time required for the amount of medicine in the body to be reduced by half—is approximately 6.2 hours. The medicine is primarily cleared from the body by the kidneys.

Q: What official body approved Glucophage for use?

Glucophage (metformin) is regulated and approved for use in the United States by the U.S. Food and Drug Administration (FDA). In Europe, it is approved by the European Medicines Agency (EMA), which ensures quality, safety, and effectiveness.

Q: Is Glucophage a 'cure' for diabetes?

Regulatory documents describe Glucophage as a management drug. It is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. It is a management tool intended to help regulate blood sugar, not a cure for the condition.

Q: Why is Glucophage sometimes prescribed for polycystic ovary syndrome (PCOS)?

Glucophage is formally indicated and approved only for the treatment of type 2 diabetes. While research has examined its use in conditions like PCOS, prescribing the medicine for this condition is outside of the official, regulatory-approved indications.

Q: What is the typical time frame to see the full effect of Glucophage on A1C?

The therapeutic effects of Glucophage are monitored by clinical biomarkers, such as the HbA1 c level, which reflects average blood sugar over two to three months. Clinical trials and medical guidelines typically assess the full, consistent therapeutic benefit of the medicine over a period of 3 to 6 months.

Q: What is the difference in how the body absorbs Glucophage versus Glucophage XR?

Regulatory pharmacokinetic information shows a difference in the rate of absorption. The immediate-release (IR) tablet reaches its highest concentration in the blood much faster (median 2.5 hours) than the extended-release (XR) tablet (median 7 hours). However, the total amount of medicine absorbed by the body is generally similar between the two formulations.

How should Glucophage be stored and disposed of?

How to Store and Dispose of Glucophage? (Metformin Hydrochloride)

Official regulatory information requires Glucophage to be stored within a controlled room temperature range, typically 20 C to 25 C (68 F to 77 F).

Storage Requirements

The medication container must be kept tightly closed and stored away from excess heat, moisture, and light. To protect children, the product must be stored out of their sight and reach, often utilizing child-resistant caps. Some extended-release forms must be swallowed whole and not crushed or chewed.

Disposal Instructions

Disposal of unused or expired Glucophage and any associated waste material must strictly follow local requirements. Regulatory guidance states that the product should not be allowed to enter drains, sewers, or the general environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.